Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2014, Article ID 708585, 8 pages
http://dx.doi.org/10.1155/2014/708585
Research Article

Early Trends in Cystatin C and Outcomes in Patients with Cirrhosis and Acute Kidney Injury

1Program of Applied Translational Research, Yale University School of Medicine, New Haven, CT 06510, USA
2Section of Nephrology, Yale University School of Medicine, New Haven, CT 06520, USA
3Clinical Epidemiology Research Center, VAMC, West Haven, CT 06516, USA
4Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA
5Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, USA
6VA-Connecticut Healthcare System, West Haven, CT 06520, USA
7Division of Nephrology, Department of Internal Medicine, Jacobi Medical Center, South Bronx, NY 10461, USA
8Division of General Internal Medicine, San Francisco VA Medical Center, University of California, San Francisco, CA 94121, USA

Received 5 December 2013; Revised 10 February 2014; Accepted 10 February 2014; Published 18 March 2014

Academic Editor: Jaime Uribarri

Copyright © 2014 Justin M. Belcher et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Arabi, Q. A. A. Ahmed, S. Haddad, A. Aljumah, and A. Al-Shimemeri, “Outcome predictors of cirrhosis patients admitted to the intensive care unit,” European Journal of Gastroenterology and Hepatology, vol. 16, no. 3, pp. 333–339, 2004. View at Google Scholar · View at Scopus
  2. E. Cholongitas, V. Calvaruso, M. Senzolo et al., “RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit,” Journal of Gastroenterology and Hepatology, vol. 24, no. 10, pp. 1639–1647, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Francoz, D. Glotz, R. Moreau, and F. Durand, “The evaluation of renal function and disease in patients with cirrhosis,” Journal of Hepatology, vol. 52, no. 4, pp. 605–613, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Ustundag, U. Samsar, S. Acikgoz et al., “Analysis of glomerular filtration rate, serum cystatin C levels, and renal resistive index values in cirrhosis patients,” Clinical Chemistry and Laboratory Medicine, vol. 45, no. 7, pp. 890–894, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Cholongitas, L. Marelli, A. Kerry et al., “Different methods of creatinine measurement significantly affect MELD scores,” Liver Transplantation, vol. 13, no. 4, pp. 523–529, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. J. M. Belcher, G. Garcia-Tsao, A. Sanyal et al., “Association of AKI with mortality and complications in hospitalized patients with cirrhosis,” Hepatology, vol. 57, no. 2, pp. 753–762, 2012. View at Publisher · View at Google Scholar
  7. K. Soto, S. Coelho, B. Rodrigues et al., “Cystatin C as a marker of acute kidney injury in the emergency department,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 10, pp. 1745–1754, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Herget-Rosenthal, G. Marggraf, J. Hüsing et al., “Early detection of acute renal failure by serum cystatin C,” Kidney International, vol. 66, no. 3, pp. 1115–1122, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Nejat, J. W. Pickering, R. J. Walker, and Z. H. Endre, “Rapid detection of acute kidney injury by plasma cystatin C in the intensive care unit,” Nephrology Dialysis Transplantation, vol. 25, no. 10, pp. 3283–3289, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Zappitelli, C. D. Krawczeski, P. Devarajan et al., “Early postoperative serum cystatin C predicts severe acute kidney injury following pediatric cardiac surgery,” Kidney International, vol. 80, no. 6, pp. 655–662, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Haase, R. Bellomo, P. Devarajan et al., “Novel biomarkers early predict the severity of acute kidney injury after cardiac surgery in adults,” Annals of Thoracic Surgery, vol. 88, no. 1, pp. 124–130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Haase-Fielitz, R. Bellomo, P. Devarajan et al., “Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery—a prospective cohort study,” Critical Care Medicine, vol. 37, no. 2, pp. 553–560, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Bell, F. Granath, J. Mrtensson, E. Löfberg, A. Ekbom, and C.-R. Martling, “Cystatin C is correlated with mortality in patients with and without acute kidney injury,” Nephrology Dialysis Transplantation, vol. 24, no. 10, pp. 3096–3102, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Briguori, G. Visconti, N. V. Rivera et al., “Cystatin C and contrast-induced acute kidney injury,” Circulation, vol. 121, no. 19, pp. 2117–2122, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Spahillari, C. R. Parikh, K. Sint et al., “Serum cystatin C-versus creatinine-based definitions of acute kidney injury following cardiac surgery: a prospective cohort study,” American Journal of Kidney Diseases, vol. 60, no. 6, pp. 922–929, 2012. View at Publisher · View at Google Scholar
  16. F. J. Hoek, F. A. W. Kemperman, and R. T. Krediet, “A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate,” Nephrology Dialysis Transplantation, vol. 18, no. 10, pp. 2024–2031, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. A. L. Gerbes, V. Gülberg, M. Bilzer, and M. Vogeser, “Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver,” Gut, vol. 50, no. 1, pp. 106–110, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Demirtaş, A. Bozbaş, A. Akbay, Y. Yavuz, and L. Karaca, “Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome,” Clinica Chimica Acta, vol. 311, no. 2, pp. 81–89, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Y. Chung, D. W. Jun, and S. A. Sung, “Diagnostic value of cystatin C for predicting acute kidney injury in patients with liver cirrhosis,” The Korean Journal of Hepatology, vol. 16, no. 3, pp. 301–307, 2010. View at Google Scholar · View at Scopus
  20. E. J. Erlandsen, E. Randers, and J. H. Kristensen, “Evaluation of the dade behring N latex cystatin C assay on the dade behring nephelometer II system,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 59, no. 1, pp. 1–8, 1999. View at Google Scholar · View at Scopus
  21. F. Wong, M. K. Nadim, J. A. Kellum et al., “Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis,” Gut, vol. 60, no. 5, pp. 702–709, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. A. S. Levey, L. A. Stevens, C. H. Schmid et al., “A new equation to estimate glomerular filtration rate,” Annals of Internal Medicine, vol. 150, no. 9, pp. 604–612, 2009. View at Google Scholar · View at Scopus
  23. M. Dobre, S. Demirjian, A. R. Sehgal, and S. D. Navaneethan, “Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis,” International Urology and Nephrology, vol. 43, no. 1, pp. 175–184, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Davenport, “Difficulties in assessing renal function in patients with cirrhosis: potential impact on patient treatment,” Intensive Care Medicine, vol. 37, no. 6, pp. 930–932, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. U. Pöge, T. Gerhardt, B. Stoffel-Wagner, H. U. Klehr, T. Sauerbruch, and R. P. Woitas, “Calculation of glomerular filtration rate based on Cystatin C in cirrhotic patients,” Nephrology Dialysis Transplantation, vol. 21, no. 3, pp. 660–664, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Demirtaş, A. Bozbaş, A. Akbay, Y. Yavuz, and L. Karaca, “Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome,” Clinica Chimica Acta, vol. 311, no. 2, pp. 81–89, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. H. S. Ahn, Y. S. Kim, S. G. Kim et al., “Cystatin C is a good predictor of hepatorenal syndrome and survival in patients with cirrhosis who have normal serum creatinine levels,” Hepatogastroenterology, vol. 59, no. 116, pp. 1168–1173, 2012. View at Google Scholar
  28. I. E. Hall, M. D. Doshi, E. D. Poggio, and C. R. Parikh, “A comparison of alternative serum biomarkers with creatinine for predicting allograft function after kidney transplantation,” Transplantation, vol. 91, no. 1, pp. 48–56, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. S. H. Kwon, J. Hyun, J. S. Jeon, H. Noh, and D. C. Han, “Subtle change of cystatin C, with or without acute kidney injury, associated with increased mortality in the intensive care unit,” Journal of Critical Care, vol. 26, no. 6, pp. 566–571, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Bachorzewska-Gajewska, J. Malyszko, E. Sitniewska et al., “NGAL (neutrophil gelatinase-associated lipocalin) and cystatin C: are they good predictors of contrast nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine?” International Journal of Cardiology, vol. 127, no. 2, pp. 290–291, 2008. View at Publisher · View at Google Scholar · View at Scopus